A Multicenter, Phase 1 Study of AB011, a Recombinant Humanized Anti-Cldn18.2 Monoclonal Antibody, As Monotherapy and Combined with Capecitabine and Oxaliplatin (CAPOX) in Patients with Advanced Solid Tumors.
JOURNAL OF CLINICAL ONCOLOGY（2023）
关键词
Treatment
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要